Phase I Pharmacokinetics And Tolerability Of PF-04236921 Following Subcutaneous Administration To Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2014
At a glance
- Drugs PF 4236921 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 22 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Aug 2010 Additional trial identifier (EudraCT2010-019770-32) identified as reported by ClinicalTrials.gov.